Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Laboratorios Hipra S A is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This action is being reviewed by 1 distinct examiner within 1 distinct art unit. Such a concentrated portfolio at this stage indicates that the company's current prosecution efforts are focused on a specific set of claims or a single application. The busiest examiner for the portfolio is HILL, MYRON G, who is overseeing 1 pending office action.
Since there is only 1 pending office action in total, HILL, MYRON G is responsible for the full scope of the company's current pending matters. The relationship between the total pending actions and the busiest examiner's workload means that the company's success in this technology area is currently tied to this examiner's review. Practitioners should analyze the 1 distinct art unit's trends to better prepare for the 1 pending office action.
This focused environment, involving 1 distinct examiner and 1 distinct art unit, provides a clear path for the company's intellectual property goals in the Biotechnology & Pharmaceuticals sector. The alignment of the busiest examiner's workload with the total pending actions simplifies the management of the portfolio's current legal standing. Understanding the tendencies of HILL, MYRON G will be important for the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, MYRON G | 1 | 66.2% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558875 | SARS-COV-2 SUBUNIT VACCINE | HILL, MYRON G | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558875 | SARS-COV-2 SUBUNIT VACCINE | HILL, MYRON G | 1671 | §103DP | Final Rejection | 4d overdue | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial